American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
May 11, 2020
Earnings Call Speaker Segments
Stephanie Prince
executiveThanks, operator, and hello everyone who has joined us today. Prior to handing things over to management, I'd like to offer a few comments about forward-looking statements. Please be aware that certain things said during this conference call regarding future expectations, plans and prospects for the company count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements indicate, due to a number of important factors, including the ones covered in the company's filings with the SEC. That takes in the company's annual report on Form 10-K for the year ended December 31, 2019, along with the definitive proxy statement for the annual meeting of shareholders scheduled for June 26, 2020. The company takes on no obligation to update the information contained in this conference call. At this point I'd like to hand the call to Ray Stachowiak, Interim President and CEO. Ray?
Ray Stachowiak
executiveThanks, Stephanie. Hello, everyone, and welcome to our conference call about first quarter 2020 earnings this afternoon. I'll start with a few opening comments, then hand things over to Craig Tagawa, who serves as our COO and CFO, to walk through the business and operational results. After that, Alexis Wallace, our Controller, will give a financial review. Once that wraps up, Craig, Alexis, Ernie Bates, and myself will take your questions. First, I want to note that Dr. Bates retired last month. The Board appointed me to serve as Interim President and Chief Executive Officer. Dr. Bates and I share a long relationship, both personally and professionally, and I hold tremendous respect and admiration for everything he built at American Shared Hospital Services across more than 40 years. Through the close of this year, Dr. Bates will stay on as Executive Chairman of the Board, and I'm happy he'll remain involved while all of us work to move the company forward. Both Dr. Bates and I care deeply about capital-intensive, advanced medical technology for hospitals, which badly need creative and flexible financing solutions. Back in 1994, I founded Shared Imaging. Shared Imaging stands as a preferred independent provider of CT, MRI, and PET/CT equipment and services. Under my leadership, Shared Imaging grew from $3 million to over $60 million a year in sales. We were profitable. Many years ago, I met Dr. Bates when he was interested in selling AMS' CT and MRI business. In 2008, I sold 50% of Shared Imaging. At that point, I invited Dr. Bates onto the Shared Imaging board, where he still serves. In 2013, I chose to retire as President of Shared Imaging after holding that role for over 19 years. As of today, I still own 50% of Shared Imaging and remain its founder owner. In 2009, Dr. Bates invited me to join the AMS Board. Since then, I've steadily grown my ownership of AMS stock. Today I'm the company's largest shareholder, with roughly 16% of the outstanding shares. Taking on this management role pleases me, because I believe I can help AMS improve and receive the credit and recognition it deserves in the markets. All the uncertainty from COVID-19 has hit the company's market value hard, even though the company holds over $30 million of tangible equity. The equipment and services we offer treat cancer patients, and cancer will not wait. I'm glad to take this on. Consequently, I believe the health care industry, and cancer treatment specifically, won't be as negatively impacted as certain other industries during this pandemic. Any softness in demand or delay in procedures ought to be made up fairly quickly. I have great belief in American Shared and its opportunities for growth. I'm here as Interim President and CEO to ensure that the company has the best leadership to realize those opportunities. Thank you for your continued support of our company. I'll hand things over now to Craig, who will walk us through the operational review for the first quarter. Craig?
Craig Tagawa
executiveThanks, Ray, and good afternoon to all of you. From our year-end conference call in early April until now, we've kept a close watch on how the COVID-19 pandemic is affecting our business. As we anticipated for the first quarter, PBRT volumes saw no material impact, because the therapies are aimed at cancer patients whose procedures shouldn't be put off indefinitely. The majority of Gamma Knife procedures likewise serve cancer patients. That said, as we mentioned on the previous quarter's call, roughly 40% of procedures might be deemed nonurgent and could potentially face delayed treatment. During the latter part of March, we did see some softening in Gamma Knife volumes, though the effect looked more modest than what we had originally expected. Gamma Knife revenue fell 15.2% in the first quarter versus the first quarter of 2019. Two factors drove that decline: First, we believe the count of procedures, which matched the same period a year earlier, was potentially affected by COVID-19. Procedures rose to 376, up from 375 in the first quarter of 2019. Procedures in the fourth quarter of 2019 came to 414. Secondly, we also saw a drop in average reimbursement rates, similar to what happened in last year's fourth quarter. The slower procedure growth was amplified by a lower overall reimbursement rate in this year's first quarter relative to the rate we got during the same period last year. First quarter revenue for the proton therapy business rose 2.1% quarter-over-quarter and 12.8% sequentially from the fourth quarter of 2019. Total proton therapy fractions in the quarter grew by 130, or 8.4% quarter-over-quarter, to 1,676, compared with 1,546 in the first quarter last year. Sequentially, fractions rose by 65, or 4%, versus 1,611 in the fourth quarter of 2019. Continuing gains in awareness and across indications of the benefits of proton therapy treatment keep driving growth. Our operating income in the first quarter of 2020 was also affected by higher SG&A costs tied to legal and other fees related to, but not limited to, the COVID-19 pandemic and the transition in senior management. We finished 2 Cobalt-60 reloads during the first quarter and signed a contract to install 1 ICON upgrade with an existing customer. Additional upgrades are also under discussion that may get completed during the balance of the year, though pinpointing the timing of these installations is especially difficult right now; and while the pace has slowed somewhat in the current environment, we've also kept holding discussions with several interested parties for additional PBRT and MRI-LINAC placements. Looking ahead, with regard to COVID-19 and the second quarter-to-date, our volumes appear to be impacted, but still remain fairly consistent with the prior year. Also, COVID-19's impact will be greater over the full 3 months of the second quarter versus only the second half of the last month of the first quarter. Like we mentioned in this morning's press release and during the last two quarterly conference calls, back in July 2019, the Centers for Medicare and Medicaid Services—CMS—put forward a proposed mandatory payment model covering radiation oncology services. The goal is to try out an episodic payment structure, or bundled payment, among particular radiation therapy providers and suppliers. According to CMS projections, roughly 40% of radiation oncology providers will be chosen at random and brought into this model, while about 60% will keep getting reimbursed under the existing fee-for-service approach. This proposed payment model would substantially change how CMS pays for radiation oncology services. For that 60% of centers left out of the proposed model, Medicare reimbursement in 2020 for the most frequently used proton therapy delivery codes is proposed to rise to approximately 15.5%, and 3.6% for the Gamma Knife. That said, as you'd expect given the current climate, we still haven't gotten any further details from CMS regarding the timing and selection specifics of the proposed payment models. Consequently, we're unable to gauge what adopting the proposed rule might mean. Even so, lower reimbursement rates or shifts in reimbursement methodology, administration for radiosurgery and radiation therapy could harm our revenues and financial results. We'll let you know about any additional new information we receive. With that, I'll hand the call over to Alexis for a detailed financial discussion. Alexis?
Alexis Wallace
executiveThank you, Craig, and good afternoon to all of you. I want to direct your attention to the first quarter earnings press release we put out this morning before I get into my prepared remarks. Should you require a copy, it's available on our website, ashes.com, under the Investors tab at Press Releases. For the 3 months ended March 31, 2020, total revenue fell 14.2% to $4,568,000, down from $5,321,000 in revenue during the first quarter of 2019. Revenue in the first quarter for the proton therapy system the company has installed at Orlando Health in Florida rose 2.1% to $1,676,000, compared with $1,642,000 for the first quarter of 2019. Sequentially, first quarter proton therapy revenue grew 12.8% from the $1,486,000 reported in the fourth quarter of 2019. For the company's Gamma Knife operations, revenue declined 15.2% to $2,892,000 in the first quarter of 2020, versus $3,411,000 in the first quarter of 2019. As Craig mentioned, this drop stemmed from lower average reimbursement at the company's retail sites relative to the first quarter last year. Gross margin in the first quarter of 2020 declined to $1,394,000, or 30.5% of revenue, compared with a gross margin of $1,137,000, or 36.4% of revenue, in the first quarter of 2019. Net loss for the first quarter of 2020 came to $135,000, or $0.02 per share. That compares with net income of $270,000, or $0.05 per share, in the first quarter of 2019. Fully diluted weighted average common shares outstanding stood at 6,153,000 for the first quarter of 2020, versus 5,886,000 for the first quarter of 2019. Adjusted EBITDA, which is a non-GAAP financial measure, totaled $1,822,000 in the first quarter of 2020, compared with $2,710,000 in the first quarter of 2019. This decrease was mainly attributable to lower net income, along with reduced depreciation and amortization tied to the company's IGRT equipment, which became fully depreciated in the fourth quarter of 2019. As of March 31, 2020, cash, cash equivalents and restricted cash amounted to $3,023,000, compared with $1,779,000 at December 31, 2019. Shareholders' equity at March 31, 2020, was $31,473,000, or $5.53 per outstanding share. That compares with shareholders' equity of $31,811,000, or $5.47 per outstanding share, at December 31, 2019; this brings the formal portion of our presentation to a close. Brandon, we'd now like to hand the call back to you for questions.
Tony Marchese
analystGood afternoon, Ray, and congrats on stepping into your new position. Right now the stock is changing hands at one-third of tangible book. That makes me wonder — from where you sit, having served on the Board and having been connected with this company, what do you think explains why that discount is there? And even more crucially, how do you intend to shrink that gap? To me, it just doesn't make sense that a business like this would trade under tangible book.
Ray Stachowiak
executiveThanks for asking that. In my view, it's a terrific question. Honestly, I can't say I fully understand how the market arrived at this valuation of, as you put it, roughly 1/3 of our book value. Frankly, one thing that drew me to invest was precisely the presence of tangible equity here, along with a sizable book value per share. So I'll leave it to the market to figure that out; however, if we're able to bring aboard a strong leadership team following Dr. Bates's retirement, then I believe we can explore what additional value we could unlock and where we could take this company from its current position.
Leonard Dunn
analystYeah. Lenny Dunn here, though that's fine. I've — honestly I've got several things to ask. Our book value ticked upward a bit despite the loss we posted. And possibly, I'm not sure whether Craig is the one who should walk us through it, but to me it's obvious this business is profitable, and I can't quite pin down where the gap comes from. So it would help if you walked through it, and after that I have one more item.
Craig Tagawa
executiveLenny, I'll have Alexis take that one.
Alexis Wallace
executiveRight, Lenny, so the increase in book value came about due to certain performance awards that were treated as legally issued shares for management. Those were granted back in 2017, and their expiration happened on March 31. As a result, they returned to the plan; thus, you'll notice that our outstanding shares in fact declined for the period. And if you look at our filing, which ought to be posted later today, there's some in-depth discussion regarding how that gets accounted for.
Leonard Dunn
analystAll right, so that clears that up for me, and I'm okay with it. Then another point: there are some very large legal and other expenses that reduced the earnings we reported. I'd like to confirm they won't happen again, so that when I build a model of what I believe the company ought to be valued at, I can account for that. Do they fall into the nonrecurring category? And could you give me at least a small breakdown?
Craig Tagawa
executiveLenny, what I'd tell you is this — as we've stated, those fees, both legal and otherwise, stemmed partly from the COVID-19 pandemic and from the changeover at the top of management. We're also hopeful that many of them will not repeat. That said, fees are going to keep showing up, legal or consulting, as we work to bring additional services into the company and pursue certain deals that might prove somewhat tougher. So even though we don't anticipate these fees simply continuing indefinitely, we do anticipate a fresh category of fees tied to our capacity to expand the business going forward.
Leonard Dunn
analystAll right. That's more or less a response, I suppose. And regarding the COVID-19 circumstance, from where I sit at least, unless something catastrophic flips it around, it appears to be coming somewhat under control, and the hospitals around us in Wisconsin and elsewhere are performing elective procedures once more. It also seems probable to me that a backlog exists of folks who would use these "elective procedures." In my view they aren't truly elective; the government simply decided, in its wisdom, that they could be postponed; yet hospitals no longer seem swamped with the need for beds for COVID-19 patients, so they're proceeding. I suspect the same pattern will hold across the country. That means we ought to get back to a more typical volume of Gamma Knife procedures. The proton beam operation is clearly running at full tilt, whereas Gamma Knife activity had been held back. Would you either poke holes in my view or offer your thoughts on it?
Craig Tagawa
executiveSure, I'll offer my thoughts. You've got it right, I believe. A lot of hospitals have begun handling elective procedures now. Because of the COVID-19 pandemic, we observed that patients, despite already having a diagnosis and a scheduled treatment, chose to put their treatment off, and that played a role. As long as people don't yet feel at ease walking in, they might keep postponing their treatment somewhat; that's among the uncertainties. Another consequence of COVID-19 was that patients weren't getting diagnosed promptly, since individuals were unwilling to enter the hospital for a diagnosis. So that too will need some time to sort itself out. Still, provided we keep making headway against the COVID-19 pandemic and people feel at ease entering the hospital, my hope is that we'll move back toward greater normalcy when it comes to treating our patients, for both Gamma Knife and PBRT.
Leonard Dunn
analystAlright. There are plenty of reasons we could really benefit from things getting back to normal. That said, it makes sense to me that every one of your prospective PBRT agreements would be paused, since hospitals probably won't want to sign off on anything major before they've got a clear picture of what lies ahead. Would you say that's right?
Craig Tagawa
executiveThat's correct. Like we've said in the past, and like I noted during my prepared remarks on today's call, PBRT has been left facing some uncertainty because of the APM model. So my sense is that we're also holding off until that situation resolves itself.
Leonard Dunn
analystAll right, and I also want to say that I value the leadership Dr. Bates has shown. I've been connected with this company for perhaps just over 20 years, though not the entire 40 that he was here. So I wanted to mention that as well.
Craig Tagawa
executiveThanks, Lenny.
Tony Kamin
analystMy question follows up somewhat on the proton beam topic. What stands out to me, I believe, is how the Orlando Center has delivered truly outstanding, consistent outcomes ever since it went in. And I realize that gets partly overshadowed by the Gamma Knife segment, which remains bigger. There's also something people tend to overlook, which is that you hold deposits, if I'm not mistaken, on 2 additional Mevion units. So my curiosity is this: given the strong PBRT performance, and recognizing that hospitals could be warier in this kind of climate, I wonder — does the COVID situation, by driving interest rates lower as a side effect, change how you view the financing landscape at present? Is there possibly some way for AMS to obtain financing that's better, more inventive, and cheaper? Or does the reluctance of people simply not wanting to commit to anything right now in this climate dominate all of that?
Craig Tagawa
executiveI'll have Ernie address that, from the perspective of business development and the sales cycle.
Ernest Bates
executiveTony, Ernie Bates here. That's a really good question. If anything, what we're seeing is that because of the uncertainty created by the pandemic, hospitals and other clinical partners are in fact seeking out creative financing options so they can get their hands on this capital-intensive equipment; so as Craig mentioned, yes, a lot of decisions are being put on hold or suspended because of the uncertainty. But discussions are still happening with these centers that have an interest in deploying this capital-intensive technology. And we're having those discussions. So to answer your question, I'd say we are that alternative financing solution for a great many, many centers.
Tony Kamin
analystYeah, that's excellent. And then, although I believe it came up during an earlier conference call, my impression is that this marks the initial instance where MR/LINAC has appeared in the press release. And it does appear to be a rather thrilling broadening, in a way, of the sort of product line that AMS is able to provide. But I'm just wondering — since it showed up in today's press release, I'd guess the company views this as an area that might potentially be a solid one for growth. So perhaps you could offer some thoughts on that.
Craig Tagawa
executiveErnie, do you want to weigh in?
Ernest Bates
executiveAbsolutely, Tony. On earlier calls, I believe I've noted that the U.S. has about 4,000 LINAC accelerators, and around 1,000 of them require replacement every 1 to 2 years, so turnover is quite high. As Craig said, with radiation oncology, APM, and episodic care, we're seeing clinical providers looking for the best ways to take advantage of chances to deliver care in a bundled setting. What makes the MR/LINAC distinct is its capacity to reshape the radiation dose according to daily shifts in the tumor's shape, size, and position, plus the surrounding healthy anatomy. The significance there is that it allows precise dose delivery with real-time tumor visualization. A LINAC by itself simply cannot accomplish that. The MR/LINAC makes it possible to essentially see what you're treating. That lets clinicians potentially deliver higher, effective radiation doses using fewer fractions. So, as I said before, under bundled payments, if you can give fewer fractions while getting reimbursement at a case rate, so to speak, that's a major benefit for the clinical provider. We're therefore very enthusiastic about what the MR/LINAC can offer.
Ray Stachowiak
executiveTony, Ray here. I want to add a little more emphasis on that point as well, since it was Dr. Bates who truly got the company moving into examining this technology, in the MR/LINAC space. And I want to be sure our investors realize how it aligns — this product aligns with the strategic vision we hold for the long term. It is a product that demands a great deal of capital. Hospitals these days are looking for financing solutions that are creative and flexible. And my belief is that American Shared is capable of being in that marketplace.
Tony Kamin
analystWonderful. And if I'm not mistaken, Elekta, the partner you've worked with for a long time, is in fact a maker of those machines — is that right?
Craig Tagawa
executiveYes, that's right.
Analyst
analystTo pick up where Tony left off with his initial couple of inquiries regarding proton therapy, my sense is that this is going to serve as a significant catalyst for AMS. So, the thing I'm hoping to learn is where you stand on the sector's trajectory when it comes to proton therapy and insurers increasingly — permitting reimbursement for claims, the expansion and engagement we've observed at Orlando Health, yet how does that look nationwide? What's the total number of units in operation? I'll stop there since those are my first 2 questions.
Craig Tagawa
executiveAlright, I'll address that by speaking about the indications. My impression is that at Orlando, a considerable volume of their patients are pediatric, and they also handle some of the tougher cases, plus they do treat prostate cases too. That said, the patient population they serve is quite complex. As far as Medicare is concerned, I believe reimbursement has posed essentially no problems; and when it comes to commercial insurance, certain carriers are known to them as ones that will cover specific indication types they collaborate with. Over time, they've developed a strong working relationship with the different insurers concerning how their patients stand to gain from protons rather than undergoing conventional radiation therapy. So my view is that this amounts to an educational journey involving the insurance companies; and I believe it's taking place gradually, and in my view it keeps improving.
Analyst
analystAlright. Regarding the margin for protons as opposed to photons, where does that stand?
Craig Tagawa
executiveWe have not shared those figures on a separate basis. Therefore, at this time, we are not providing that breakdown.
Analyst
analystIn fact, I think there were a few units, a few locations in California that the company was pursuing quite aggressively a year ago. Any update on that? I understand it's paused and so forth, but what kinds of talks are happening? What's the status? Are we 50% done? 60%? Could you provide a bit more detail on that?
Craig Tagawa
executiveI'll have Ernie respond to that regarding our position in Southern California.
Ernest Bates
executiveNick, talks are still ongoing with a party down in Southern California. Something important to grasp regarding protons: the sales process is quite lengthy and intricate. Frequently, these cycles run beyond 2 to 3 years; thus, we've been involved in Southern California for a while now; even so, enthusiasm remains quite robust among clinicians when it comes to building a single room center. Therefore, we'll keep updating you as we pursue these opportunities in that region.
Ray Stachowiak
executiveNick, there's another point I want to bring up, specifically about U.S. centers. In the United States, you'll find more than 35 proton centers, and during roughly the last 2 years, almost all of those newly opened locations have involved single-room or otherwise compact configurations — which is to say, no more than 2 rooms. Dr. Bates held the view, going back many years, that proton therapy's future — or rather, how widely proton radiation therapy would be adopted — wouldn't come from continuing to build extremely costly 4- or 5-room centers, which in many instances carried price tags exceeding $250 million. Instead, he expected broader uptake of single-room options, since those demand substantially less capital and come with far lower ROI thresholds. That is precisely the pattern we've observed. And Mevion, which manufactures a compact single-room offering, recently announced letters of intent for prospective new sites in Danbury, Connecticut as well as in Texas. So the momentum keeps moving in that same direction.
Ray Stachowiak
executiveI appreciate all of you being with us on this call. Taking on this new position has me genuinely enthusiastic, and I can't wait to contribute something meaningful to AMS. Should anything come up that you'd like to ask about ahead of our Q2 earnings call, which happens in the middle of August, don't hesitate to reach out. Take care of yourselves, remain healthy, and enjoy the rest of your week. That's all from us.
Operator
operatorThanks. That wraps up the call for today, everyone. We appreciate your participation. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.